KZR

Kezar Life Sciences, Inc. (NASDAQ:KZR) is a clinical-stage biotechnology company founded in 2015 and headquartered in South San Francisco, California. The company went public in June 2018 and focuses on discovering and developing novel small molecule therapeutics to address unmet medical needs in immune-mediated diseases and cancer. As a clinical-stage biotech, Kezar does not yet generate product revenue and is primarily funded through equity financing while advancing its drug candidates through various phases of clinical trials.